Research delivers insight into the Asthma - Pipeline Review, H1 2017

Asthma - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

To access full report with TOC, please visit Asthma - Pipeline Review, H1 2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 14, 45, 33, 1, 123 and 25 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 25 and 7 molecules, respectively.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4D Pharma PLC AB Science SA AbbVie Inc Abeome Corp Accolade Pharmaceuticals LLC Adamis Pharmaceuticals Corp Advanced Inhalation Therapies (AIT) Ltd Advinus Therapeutics Ltd ALK-Abello A/S Allergopharma GmbH & Co KG Almirall SA Alteogen Inc Amakem NV Amgen Inc AnaptysBio Inc AnGes MG Inc Antisense Therapeutics Ltd Apollo Endosurgery Inc ARA Healthcare Pvt Ltd Ario Pharma Ltd ASIT Biotech SA Aslan Pharmaceuticals Pte Ltd Astellas Pharma Inc AstraZeneca Plc Asubio Pharma Co Ltd Aurigene Discovery Technologies Ltd Axikin Pharmaceuticals Inc Bioncotech Therapeutics SL Biotec Pharmacon ASA Boehringer Ingelheim GmbH CalciMedica Inc Celldex Therapeutics Inc Cellular Biomedicine Group Inc Celon Pharma SA Chiesi Farmaceutici SpA Circassia Pharmaceuticals Plc Cognosci Inc Cumberland Pharmaceuticals Inc Cynata Therapeutics Ltd Cytokinetics Inc Daiichi Sankyo Company Ltd Denceptor Therapeutics Ltd Enterprise Therapeutics Ltd F. Hoffmann-La Roche Ltd Foresee Pharmaceuticals LLC Fountain Biopharma Inc Genentech Inc GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Griffin Discoveries BV Han Wha Pharma Co Ltd Hydra Biosciences Inc iCeutica Inc iCo Therapeutics Inc. Immupharma Plc InKemia IUCT Group SA Intech Biopharm Ltd Invion Ltd Jiangsu Hansoh Pharmaceutical Group Co Ltd Johnson & Johnson Kissei Pharmaceutical Co Ltd KPI Therapeutics Inc Kyowa Hakko Kirin Co Ltd Lead Discovery Center GmbH MedImmune LLC Merck & Co Inc Mitsubishi Tanabe Pharma Corp Mundipharma International Ltd Mycenax Biotech Inc NAL Pharmaceuticals Ltd NeoPharm Co Ltd Novartis AG Omeros Corp Ono Pharmaceutical Co Ltd OPKO Health Inc Orbis Biosciences Inc Orchid Pharma Ltd Orion Oyj Oxagen Ltd Palatin Technologies Inc Panacea Biotec Ltd Paradigm Biopharmaceuticals Ltd Pfizer Inc Pharmaxis Ltd Pieris Pharmaceuticals Inc Polyphor Ltd Progenra Inc Promedior Inc Prommune Inc Pulmagen Therapeutics LLP Pulmatrix Inc Pulmokine Inc Qu Biologics Inc Qurient Co Ltd Re-Pharm Ltd Regeneron Pharmaceuticals Inc Respiratorius AB ReveraGen BioPharma Inc Rhizen Pharmaceuticals SA Saje Pharma LLC Shire Plc sterna biologicals Gmbh & Co KG Sumitomo Dainippon Pharma Co Ltd Sun Pharma Advanced Research Company Ltd Sunovion Pharmaceuticals Inc Swecure AB Synermore Biologics Co Ltd Syntrix Biosystems Inc TaiwanJ Pharmaceuticals Co Ltd Teva Pharmaceutical Industries Ltd Therabron Therapeutics Inc Theravance Biopharma Inc Tolerys SA United BioPharma Inc Vectura Group Plc Verona Pharma Plc WhanIn Pharmaceutical Co Ltd Xencor Inc Yungjin Pharm Co Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###